N-[(1R,2R)-2-(2,5-dichloropyrimidin-4-ylamino)cyclohexyl]acetamide | 1022971-87-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: N-[(1R,2R)-2-(2,5-dichloropyrimidin-4-ylamino)cyclohexyl]acetamide
• 英文别名: N-[(1R,2R)-2-(2,5-Dichloro-pyrimidin-4-ylamino)-cyclohexyl]-acetamide；N-[(1R,2R)-2-[(2,5-dichloropyrimidin-4-yl)amino]cyclohexyl]acetamide
• CAS: 1022971-87-4
• 化学式: C₁₂H₁₆Cl₂N₄O
• 分子量: 303.191
• InChiKey: IXJAJQXUNZJCHE-NXEZZACHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  66.9
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-ethyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-amine 、 N-[(1R,2R)-2-(2,5-dichloropyrimidin-4-ylamino)cyclohexyl]acetamide 在 盐酸 作用下， 以 1,4-二氧六环 、 甲乙醚 为溶剂， 生成 N-{(1R,2R)-2-[5-chloro-2-(3-ethyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ylamino)pyrimidin-4-ylamino]cyclohexyl}acetamide
  参考文献：
  名称：

  Methanesulfonamido-cyclohexylamine derivatives of 2,4-diaminopyrimidine as potent ALK inhibitors

  摘要：

  The incorporation of R,R-1,2-diaminocyclohexane at C4 in a series of 2,4-diaminopyrimidines led to a number of ALK inhibitors in which optimized activity was achieved by conversion of the 2-amino group into a methanesulfonamide. Tumor growth inhibition was observed when an orally bioavailable analog was evaluated in a Karpas-299 tumor xenograft mouse model. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.05.040
• 作为产物：
  描述：

  (1R,2R)-1,2-diaminocyclohexane 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 0.33h， 生成 N-[(1R,2R)-2-(2,5-dichloropyrimidin-4-ylamino)cyclohexyl]acetamide
  参考文献：
  名称：

  Methanesulfonamido-cyclohexylamine derivatives of 2,4-diaminopyrimidine as potent ALK inhibitors

  摘要：

  The incorporation of R,R-1,2-diaminocyclohexane at C4 in a series of 2,4-diaminopyrimidines led to a number of ALK inhibitors in which optimized activity was achieved by conversion of the 2-amino group into a methanesulfonamide. Tumor growth inhibition was observed when an orally bioavailable analog was evaluated in a Karpas-299 tumor xenograft mouse model. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.05.040

文献信息

• [EN] SUBSTITUTED PYRIMIDINES FOR THE TREATMENT OF CANCER<br/>[FR] PYRIMIDINES SUBSTITUÉES POUR LE TRAITEMENT DU CANCER
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2010106097A1

  公开（公告）日：2010-09-23

  The present invention encompasses compounds of general formula (1) wherein B, R1 to R5, Rx, m and n are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use in such treatment.

  本发明涵盖了一般式（1）中的化合物，其中B、R1至R5、Rx、m和n的定义如权利要求书中所述，这些化合物适用于治疗由细胞过度或异常增殖特征的疾病，并且适用于此类治疗。
• FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS
  申请人：Ahmed Gulzar

  公开号：US20090221555A1

  公开（公告）日：2009-09-03

  The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , A 1 , A 2 , A 3 , A 4 , and A 5 , are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.

  本发明提供公式I或II化合物或其药学上可接受的盐形式，其中R1、R2、R3、R4、R5、A1、A2、A3、A4和A5如本文所定义。公式I或II化合物具有ALK和/或c-Met抑制活性，可用于治疗增殖性疾病。
• NEW COMPOUNDS
  申请人：SAPOUNTZIS Ioannis

  公开号：US20110071158A1

  公开（公告）日：2011-03-24

  The present invention encompasses compounds of general formula (1) wherein B, R 1 to R 5 , R x , m and n are defined as in claim 1 , which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use in such treatment.

  本发明涵盖了一般式（1）的化合物，其中B、R1至R5、Rx、m和n如权利要求1所定义，适用于治疗由过度或异常细胞增殖所特征的疾病，并且它们在这种治疗中的使用。
• Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors
  申请人：Ahmed Gulzar

  公开号：US20120165519A1

  公开（公告）日：2012-06-28

  The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , A 1 , A 2 , A 3 , A 4 , and A 5 , are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.

  本发明提供了式I或II的化合物或其药学上可接受的盐形式，其中R1、R2、R3、R4、R5、A1、A2、A3、A4和A5如本文所定义。式I或II的化合物具有ALK和/或c-Met抑制活性，并可用于治疗增生性疾病。
• Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-MET inhibitors
  申请人：Ahmed Gulzar

  公开号：US08552186B2

  公开（公告）日：2013-10-08

  The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R1, R2, R3, R4, R5, A1, A2, A3, A4, and A5, are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.

  本发明提供了式I或II的化合物或其药学上可接受的盐形式，其中R1、R2、R3、R4、R5、A1、A2、A3、A4和A5的定义如本文所述。式I或II的化合物具有ALK和/或c-Met抑制活性，可用于治疗增殖性疾病。